451 related articles for article (PubMed ID: 34596728)
1. Black fungus immunosuppressive epidemic with Covid-19 associated mucormycosis (zygomycosis): a clinical and diagnostic perspective from India.
Singh K; Kumar S; Shastri S; Sudershan A; Mansotra V
Immunogenetics; 2022 Apr; 74(2):197-206. PubMed ID: 34596728
[TBL] [Abstract][Full Text] [Related]
2. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India.
Singh AK; Singh R; Joshi SR; Misra A
Diabetes Metab Syndr; 2021; 15(4):102146. PubMed ID: 34192610
[TBL] [Abstract][Full Text] [Related]
3. Covid-19 and mucormycosis (Black Fungus): An epidemic within the pandemic.
Gambhir RS; Aggarwal A; Bhardwaj A; Kaur A; Sohi RK; Mehta S
Rocz Panstw Zakl Hig; 2021; 72(3):239-244. PubMed ID: 34553877
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 and mucormycosis syndemic: double health threat to a collapsing healthcare system in India.
Rocha ICN; Hasan MM; Goyal S; Patel T; Jain S; Ghosh A; Cedeño TDD
Trop Med Int Health; 2021 Sep; 26(9):1016-1018. PubMed ID: 34117677
[TBL] [Abstract][Full Text] [Related]
5. Long-term Outcome of Coronavirus Disease-associated Mucormycosis: 1-year Follow-up Study from India.
Agrawal P; Singh AP; Chakotiya PS; Kumar V; Gautam A; Kumar D
J Assoc Physicians India; 2024 Jun; 72(6):44-48. PubMed ID: 38881134
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 associated mucormycosis - An emerging threat.
Chao CM; Lai CC; Yu WL
J Microbiol Immunol Infect; 2022 Apr; 55(2):183-190. PubMed ID: 35074291
[TBL] [Abstract][Full Text] [Related]
7. The Past, Present and Future of COVID-19 Associated Mucormycosis: A Rapid Review.
Sarfraz Z; Sarfraz A; Jaiswal V; Poudel S; Bano S; Hanif M; Singh Shrestha P; Sarfraz M; Michel G; Cherrez-Ojeda I
J Prim Care Community Health; 2022; 13():21501319221099476. PubMed ID: 35587142
[TBL] [Abstract][Full Text] [Related]
8. The impact of mucormycosis (black fungus) on SARS-CoV-2-infected patients: at a glance.
Islam MR; Rahman MM; Ahasan MT; Sarkar N; Akash S; Islam M; Islam F; Aktar MN; Saeed M; Harun-Or-Rashid M; Hosain MK; Rahaman MS; Afroz S; Bibi S; Rahman MH; Sweilam SH
Environ Sci Pollut Res Int; 2022 Oct; 29(46):69341-69366. PubMed ID: 35986111
[TBL] [Abstract][Full Text] [Related]
9. The cross-talk between mucormycosis, steroids and diabetes mellitus amidst the global contagion of COVID-19.
Dwivedi S; Choudhary P; Gupta A; Singh S
Crit Rev Microbiol; 2023 May; 49(3):318-333. PubMed ID: 35324372
[TBL] [Abstract][Full Text] [Related]
10. [COVID-19 associated mucormycosis. A case in Argentina].
Aparicio M; Tuculet B; Rivolier MG; Forte A; Vila A
Medicina (B Aires); 2022; 82(2):304-307. PubMed ID: 35417397
[TBL] [Abstract][Full Text] [Related]
11. Antibody Responses and CNS Pathophysiology of Mucormycosis in Chronic SARS Cov-2 Infection: Current Therapies Against Mucormycosis.
Beeraka NM; Liu J; Sukocheva O; Sinelnikov MY; Fan R
Curr Med Chem; 2022; 29(32):5348-5357. PubMed ID: 35538800
[TBL] [Abstract][Full Text] [Related]
12. Coronavirus disease-associated mucormycosis (CAM): A case control study during the outbreak in India.
Wasiq M; K R; Gn A
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443518
[TBL] [Abstract][Full Text] [Related]
13. Association of Serum Iron Studies in COVID Associated Mucormycosis with Stage of the Disease.
Rao C; R M
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443509
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for COVID-19 associated mucormycosis in India: A case control study.
Patel AK; Bakshi H; Shah K; Patel S; Patel T; Patel K; Patel KK
Med Mycol; 2022 Jul; 60(7):. PubMed ID: 35709394
[TBL] [Abstract][Full Text] [Related]
15. Mucormycosis, past and present: a comprehensive review.
Gupta I; Baranwal P; Singh G; Gupta V
Future Microbiol; 2023 Feb; 18():217-234. PubMed ID: 36970978
[TBL] [Abstract][Full Text] [Related]
16. A systematic review on SARS-CoV-2-associated fungal coinfections.
Soni S; Namdeo Pudake R; Jain U; Chauhan N
J Med Virol; 2022 Jan; 94(1):99-109. PubMed ID: 34570905
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology, clinical presentation and management of COVID-19 associated mucormycosis: A single centre experience from Pune, Western India.
Dravid A; Kashiva R; Khan Z; Bande B; Memon D; Kodre A; Mane M; Pawar V; Patil D; Kalyani S; Raut P; Bapte M; Saldanha C; Chandak D; Patil T; Reddy S; Bhayani K; Suresh L; Dillibabu V; Srivastava S; Khandelwal S; More S; Shakeel A; Pawar M; Nande P; Harshe A; Kadam S; Hallikar S; Kamal N; Andrabi D; Bodhale S; Raut A; Chandrashekhar S; Raman C; Mahajan U; Joshi G; Mane D
Mycoses; 2022 May; 65(5):526-540. PubMed ID: 35212032
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology and Pathophysiology of COVID-19-Associated Mucormycosis: India Versus the Rest of the World.
Muthu V; Rudramurthy SM; Chakrabarti A; Agarwal R
Mycopathologia; 2021 Dec; 186(6):739-754. PubMed ID: 34414555
[TBL] [Abstract][Full Text] [Related]
19. Mucormycosis and COVID-19 pandemic: Clinical and diagnostic approach.
Azhar A; Khan WH; Khan PA; Alhosaini K; Owais M; Ahmad A
J Infect Public Health; 2022 Apr; 15(4):466-479. PubMed ID: 35216920
[TBL] [Abstract][Full Text] [Related]
20. COVID associated mucormycosis: A preliminary study from a dedicated COVID Hospital in Delhi.
Meher R; Wadhwa V; Kumar V; Shisha Phanbuh D; Sharma R; Singh I; Rathore PK; Goel R; Arora R; Garg S; Kumar S; Kumar J; Agarwal M; Singh M; Khurana N; Sagar T; Manchanda V; Saxena S
Am J Otolaryngol; 2022; 43(1):103220. PubMed ID: 34547717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
